Ocean Biomedical, Inc. (OCEA)

1,4100 -0,0800 (-5,37%) Alla chiusura: 04:00PM EDT

Ocean Biomedical, Inc.

Room 325, 55 Claverick Street
Providence, RI 02903
United States
401 444 7375
https://www.oceanbiomedical.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Elizabeth Ng M.B.A.	CEO & Director	N/D	N/D	1957
Dr. Inderjote Kathuria M.B.A., M.D.	Chief Strategy Officer	N/D	N/D	1967
Dr. Chirinjeev Baboo Kathuria M.B.A., M.D.	Founder & Executive Chairman of the Board	N/D	N/D	1965
Dr. Jack A. Elias M.D.	Founder, Chairman of Scientific Advisory Board & Independent Director	N/D	N/D	1951
Dr. Jonathan Kurtis M.D., Ph.D.	Founder, Chairman of Scientific Advisory Board & Director	N/D	N/D	1969
Ms. Jolie G. Kahn C.P.A., Esq.	Chief Financial Officer	N/D	N/D	1965
Mr. Robert John Sweeney	Chief Accounting Officer & Assistant Secretary	N/D	N/D	1965

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.

Governance aziendale

L'ISS Governance QualityScore di Ocean Biomedical, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.